The Curious Case of India and Big Pharma
14 September 2016
Amid criticism from the United States and elsewhere, India has debuted its first national IP policy. Simon Lee examines the interplay between the new IP policy and India’s lucrative pharmaceuticals industry.
To continue reading this article, please Login or Register to be a subscriber
